Juarez, Jaily .

HRN: 28-69-74  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/16/2026
CEFTRIAXONE 1G (VIAL)
03/16/2026
03/22/2026
IV
2G
OD
TYPHOID ENCEPHALOPATHY
Checking Initial Appropriateness 
03/17/2026
METRONIDAZOLE 500MG (TAB)
03/17/2026
03/23/2026
IV
500MG
Q6
INTRACRANIAL MASS LEFT LIKELY ABSCESS CANNOT TOTALLY RULE OUT BACTERIAL MENINGITIS
Checking Initial Appropriateness 
03/17/2026
CEFTRIAXONE 1G (VIAL)
03/17/2026
03/23/2026
IV
2g
Q12
INTRACRANIAL MASS LEFT LIKELY ABSCESS CANNOT TOTALLY RULE OUT BACTERIAL MENINGITIS
Checking Initial Appropriateness 
03/19/2026
ACICLOVIR 250MG VIAL (I.V. INFUSION)
03/19/2026
03/26/2026
IV INFUSION
660mg
Q8hrs
Viral Encephalitis
Remove - Pending Acceptance
03/23/2026
ACICLOVIR 400MG (TAB)
03/23/2026
03/27/2026
PO
400mg
TID
Oral Herpes
Remove - Pending Acceptance
03/24/2026
MUPIROCIN 2%, 15G (TUBE)
03/24/2026
03/31/2026
TOPICAL
Apply On Affected Area
BID
Infected Wound, Upper Lip
Checking Initial Appropriateness 
03/24/2026
LEVOFLOXACIN 5MG/ML, 100ML (VIAL)
03/24/2026
03/31/2026
IV
750mg
OD
VAP (S. Marcenscens)
Checking Initial Appropriateness 
03/24/2026
COTRIMOXAZOLE 960MG (TAB)
03/24/2026
03/31/2026
PER NGT
1 Tab
TID
VAP (S. Marcescens)
Remove - Pending Acceptance
03/28/2026
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
03/28/2026
04/04/2026
IV
750
OD
CNS Infection
Remove - Pending Acceptance
03/28/2026
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
03/28/2026
04/04/2026
TOPICAL
Apply To Affected Area
BID
Skin Infection
Remove - Pending Acceptance
03/31/2026
ACICLOVIR 400MG (TAB)
03/31/2026
04/14/2026
PO
400
TID
HSV
Remove - Pending Acceptance

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: